Pioneering a new era in neurodegenerative care, Taumex is leading the charge with advanced molecular therapies targeting tau proteins—offering new hope for patients and transforming the way Alzheimer’s is treated globally.
Alzheimer's disease remains one of the most devastating and elusive neurological disorders of our time, affecting over 55 million people worldwide and costing the global economy over $1 trillion annually. Despite decades of research, effective treatments have remained largely out of reach. Most available therapies provide only temporary symptom relief and target amyloid-beta proteins, which have failed to yield meaningful long-term benefits. In this challenging landscape, Taumex Therapeutics is emerging as a beacon of hope.
Based in the United States and co-founded by entrepreneur Mr. Ali Taraghijah and neuroscientist Professor Koorosh Shahpasand, Taumex Therapeutics is pioneering a groundbreaking new therapy that takes an entirely different approach. At the heart of their innovation is a proprietary antibody known as pT231-tau, designed to target the pathological tau proteins that are now recognized as the true drivers of Alzheimer's progression.
Unlike traditional drugs, Taumex's therapeutic strategy is disease-modifying. The antibody pT231-tau neutralizes a specific form of hyperphosphorylated tau protein implicated in neuron death. This form, known as pT231, is one of the earliest and most toxic variations, triggering the collapse of microtubule structures essential for brain function. By targeting this precise pathology, Taumex aims not just to delay the disease but to stop it in its tracks.
Preclinical animal trials have shown exceptional promise, with the antibody preventing cognitive decline and halting neurodegeneration. Phase 1 human clinical trials have confirmed both the safety and the bioactivity of the therapy, with no severe adverse effects reported. Now, the project has advanced to Phase 2a clinical trials, approved by the Kurdistan Medical Ethics Committee and underway in certified hospitals in Erbil, Iraq. Over the next 12 months, 60 patients will be enrolled to assess the therapy's safety, tolerability, and early-stage efficacy.
The path forward is ambitious but strategically sound. The company has partnered with a seasoned Contract Research Organization (CRO), ensuring professional oversight and adherence to international clinical standards. The antibody has been manufactured under Good Manufacturing Practices (GMP) and is ready for broader clinical deployment. The estimated cost of the Phase 2a trial is $4 million, with projections of a 20x return on investment following successful outcomes and subsequent licensing or acquisition deals.
Beyond the science, Taumex represents a new vision for global biotech. Mr. Ali Taraghijah, a seasoned investor and industrial leader based in Dubai, brings decades of experience in cross- sector innovation—from pharmaceuticals and agriculture to artificial intelligence and fintech. His leadership is instrumental in transforming Taumex from a research initiative into a commercial reality with global relevance.
The potential impact of this therapy cannot be overstated. As the population ages, the burden of Alzheimer's will continue to rise. A disease-modifying therapy that directly addresses the core mechanisms of neurodegeneration would be a seismic shift—for patients, families, healthcare systems, and the global economy.
Disclaimer and Regulatory Information for IRTM.
Digital assets are subject to a range of risks, including high price volatility. Engaging in transactions involving digital assets may result in significant financial losses and may not be suitable for all users. Digital asset markets and platforms are not subject to the same regulatory oversight, customer safeguards or consumer protections as traditional financial systems and are influenced by evolving regulatory frameworks globally.
Digital assets generally do not carry legal tender status and are not insured by deposit protection schemes. Past performance of any digital asset is not indicative of future performance, and should not be relied upon as a guarantee of future outcomes.
IRTM, Inc is committed to compliance with applicable financial regulations. Where required, IRTM holds licenses or authorizations to conduct money transmission and/or virtual asset services, including licensing by Dubai, UAE or international regulatory authorities.
IRTM is also a technology provider and does not offer regulated financial or advisory services. You, as the service provider, are solely responsible for the services you provide to your users, including ensuring compliance with all applicable licensing, regulatory and legal obligations.
For developers and partners, please refer to the IRTM Developer Terms of Service for additional guidance.
© 2025 IRTM Group, Inc. All rights reserved
Design & Development | Parameta Technology